This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.
Horizon Therapeutics (HZNP) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 74.00% and 13.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Beats on Q3 Earnings & Sales, Ups Sales View
by Zacks Equity Research
Vertex (VRTX) beats estimates for both earnings and sales and raises revenue guidance for 2020.
Blueprint Medicines (BPMC) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.
Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q3 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) Q3 top-line results are expected to reflect the impact of coronavirus on sales of Humira, Imbruvica and Venclexta.
Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) misses on both earnings and sales for the third quarter. The company reiterates its revenue guidance for 2020.
Horizon (HZNP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Horizon (HZNP) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 2.
Merck (MRK) Beats on Q3 Earnings & Sales, Updates Guidance
by Zacks Equity Research
Merck (MRK) increases earnings guidance while tightening sales outlook for the year. Shares up in pre-market trading.
Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day
Horizon Therapeutics (HZNP) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.
HCA Healthcare (HCA) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter 2020 results are likely to reflect higher revenues owing to the gradual rise in patient volumes following the easing of government restrictions.
Is Horizon Therapeutics Public Limited (HZNP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (HZNP) Outperforming Other Medical Stocks This Year?
Vertex to End Phase II Study on AAT Deficiency Candidate
by Zacks Equity Research
Vertex (VRTX) to discontinue phase II study on VX-814 based on the liver enzyme elevations observed and the determination that it would be difficult to safely achieve targeted exposure levels.
Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP)
by Zacks Equity Research
Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers' Opdivo & Yervoy Win FDA Nod for Mesothelioma
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo in combination with Yervoy gets an FDA approval for malignant pleural mesothelioma.
Bristol Myers to Buy MyoKardia to Aid Cardiovascular Franchise
by Zacks Equity Research
Bristol Myers (BMY) offers $13.1 billion to acquire MyoKardia for diversifying its cardiovascular product portfolio. The transaction is expected to close in the fourth quarter of 2020.
AMAG (AMAG) to be Acquired by Covis Group for $647 Million
by Zacks Equity Research
AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.
bluebird's MAA for Elivaldogene Autotemcel Accepted by EMA
by Zacks Equity Research
bluebird's (BLUE) MAA for elivaldogene autotemcel gene therapy for the treatment of patients with cerebral adrenoleukodystrophy is accepted by the the European Medicines Agency.
Galapagos Begins Dosing With GLPG3970 in Psoriasis Study
by Zacks Equity Research
Galapagos (GLPG) doses the first patient in an early-stage study on its Toledo compound GLPG3970 for treating psoriasis. The same is also being studied for ulcerative colitis and rheumatoid arthritis.
4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes
by Indrajit Bandyopadhyay
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
AVROBIO's (AVRO) gene therapy candidate for Gaucher disease, AVR-RD-02, gets orphan drug designation from the European Commission.
Eiger Down on Disappointing Results From Coronavirus Study
by Zacks Equity Research
Eiger (EIGR) declines on disappointing study results on candidate, peginterferon lambda-1a (lambda), in outpatients with mild and uncomplicated COVID-19.
Blueprint Medicines' Gist Drug Ayvakyt Gets EU Approval
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakyt gains a conditional marketing approval from the European Commission for unresectable/metastatic gastrointestinal stromal tumors harboring the PDGFRA D842V mutation.
Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants
by Zacks Equity Research
Vertex (VRTX) wins an FDA approval for Kalydeco to treat cystic fibrosis in infants aged four to less than six months with minimum one mutation in their CFTR gene that is responsive to Kalydeco.